Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
Launched by MEDICAL RESEARCH COUNCIL · Apr 15, 2003
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* Compare the survival rate in patients with newly diagnosed small cell lung cancer and good performance status treated with an intensive regimen of ifosfamide/carboplatin/etoposide with mid-cycle vincristine (VICE) vs. standard chemotherapy followed, as feasible, by thoracic radiotherapy.
* Compare the adverse effects of treatment and quality of life (including psychological distress, physical status, and functional status and global quality of life) in these patients.
* Compare the Rotterdam Symptom Checklist vs. the EORTC QLQ-C30 and LC13 quality-of-life questionnaires in re...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Microscopically proven small cell lung cancer
- • Diagnosis based on bronchial, mediastinal, pleural, lung, or lymph node biopsy, sputum cytology, or bronchial brushing or fine needle aspirate cytology
- • No pleural fluid cytology
- • No prior therapy
- PATIENT CHARACTERISTICS:
- Age:
- • Any age
- Performance status:
- • WHO 0-2
- Hematopoietic:
- • WBC more than 3,000
- • ANC more than 1,500
- • Platelets more than 100,000
- Hepatic/Renal:
- • Alkaline phosphatase, aminotransferase, sodium, and LDH normal or no more than 1 of them abnormal
- • Creatinine or urea normal
- • Creatinine clearance or GFR more than 65 mL/min
- Other:
- • No clinical evidence of infection
- • No prior or concurrent malignancy that interferes with protocol treatments or comparisons
- • No other condition that contraindicates treatment
- • Willing and able to complete quality-of-life questionnaires
- • Hospital Anxiety and Depression Scale, Rotterdam Symptom Checklist, and EORTC questionnaires completed prior to randomization
- PRIOR CONCURRENT THERAPY:
- Biologic therapy:
- • See Disease Characteristics
- Chemotherapy:
- • See Disease Characteristics
- Endocrine therapy:
- • See Disease Characteristics
- Radiotherapy:
- • See Disease Characteristics
- Surgery:
- • See Disease Characteristics
About Medical Research Council
The Medical Research Council (MRC) is a prominent UK-based organization dedicated to advancing medical research and improving health outcomes through innovative scientific inquiry. As a leading sponsor of clinical trials, the MRC fosters collaboration among researchers, healthcare professionals, and industry partners to facilitate cutting-edge studies that address critical health challenges. With a strong emphasis on evidence-based research, the MRC supports a diverse portfolio of clinical trials aimed at translating scientific discoveries into practical applications, ultimately enhancing patient care and public health. Their commitment to rigorous ethical standards and regulatory compliance ensures the integrity and reliability of the research they sponsor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, England, United Kingdom
Patients applied
Trial Officials
David J. Girling, MD
Study Chair
Medical Research Council
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials